Xiaoling Li, PhD
Associate Research ScientistDownloadHi-Res Photo
About
Copy Link
Titles
Associate Research Scientist
Associate Research Scientist, Urology
Departments & Organizations
- Mu Lab
Education & Training
- Postdoc Researcher
- UT Southwestern Medical Center
- PhD
- Zhejiang University, Life Sciences Institute/Cell Biology
Research
Copy Link
Overview
Public Health Interests
Cancer; Genetics, Genomics, Epigenetics
Research at a Glance
Yale Co-Authors
Frequent collaborators of Xiaoling Li's published research.
Ping Mu, PhD
Su Deng, PhD
Yaru Xu
Siyuan Cheng
Yuyin Jiang
Publications
Featured Publications
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer
Li X, Wang Y, Deng S, Zhu G, Wang C, Johnson N, Zhang Z, Tirado C, Xu Y, Metang L, Gonzalez J, Mukherji A, Ye J, Yang Y, Peng W, Tang Y, Hofstad M, Xie Z, Yoon H, Chen L, Liu X, Chen S, Zhu H, Strand D, Liang H, Raj G, He H, Mendell J, Li B, Wang T, Mu P. Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer. Cancer Cell 2023, 41: 1427-1449.e12. PMID: 37478850, PMCID: PMC10530398, DOI: 10.1016/j.ccell.2023.06.010.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsProstate cancerTherapy resistanceTumor heterogeneityTumor mutational burdenCell-intrinsic mechanismsPromote tumor heterogeneityMutational burdenTargeted therapyDriver mutationsPCa cellsCancer cellsHuman cancersMutated genesCancerMutational signaturesProstateTumorTherapyFOXA1APOBEC proteinsAPOBEC3BEP300Molecular brakeMutationsSYNCRIPLoss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation
Zhang Z, Zhou C, Li X, Barnes S, Deng S, Hoover E, Chen C, Lee Y, Zhang Y, Wang C, Metang L, Wu C, Tirado C, Johnson N, Wongvipat J, Navrazhina K, Cao Z, Choi D, Huang C, Linton E, Chen X, Liang Y, Mason C, de Stanchina E, Abida W, Lujambio A, Li S, Lowe S, Mendell J, Malladi V, Sawyers C, Mu P. Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. Cancer Cell 2020, 37: 584-598.e11. PMID: 32220301, PMCID: PMC7292228, DOI: 10.1016/j.ccell.2020.03.001.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAndrogen AntagonistsAnimalsApoptosisBiomarkers, TumorCell ProliferationChromatinDNA HelicasesDNA-Binding ProteinsDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHigh-Throughput Screening AssaysHumansMaleMiceProstatic Neoplasms, Castration-ResistantReceptors, AndrogenRNA, Small InterferingTranscription FactorsTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsAntiandrogen resistanceChromatin dysregulationCHD1 lossProstate cancerGenomic copy number alterationsRNA-seq analysisResistance to hormonal therapyCopy number alterationsAR-targeted therapiesMetastatic prostate cancerATAC-seqClosed chromatinRNA-seqTranscriptional plasticityTranscription factorsFunctional screeningTranscriptomic changesMechanisms of resistanceHormone therapyLineage programsChromatinCHD1Global changeIntegrated analysisTherapy
2026
Editorial: APOBEC and ADAR in oncogenesis: from molecular mechanisms to therapeutic targets
Li X, Wang Y, Mu P. Editorial: APOBEC and ADAR in oncogenesis: from molecular mechanisms to therapeutic targets. Frontiers In Genetics 2026, 17: 1827626. PMID: 42039701, PMCID: PMC13105454, DOI: 10.3389/fgene.2026.1827626.Commentaries, Editorials and LettersAltmetricA dual role of EZH2 in regulating A-to-I RNA editing and mRNA stability through ADAR
Yi Y, Li Y, Wang R, Yu X, Liu Q, Yum C, Zhang Y, Qiao Y, Szczepanski A, Wu S, Li Q, Fazli L, Shen J, Wang X, Li X, Mu P, Schaeffer E, Hundley H, Niu H, Chinnaiyan A, Wang L, Shi J, Jin J, Dong X, Zhao W, Chen K, Cao Q. A dual role of EZH2 in regulating A-to-I RNA editing and mRNA stability through ADAR. Nature Communications 2026, 17: 4421. PMID: 41882000, DOI: 10.1038/s41467-026-71207-3.Peer-Reviewed Original ResearchAltmetricConceptsInterleukin enhancer binding factor 2RNA editingEnhancer of zeste homologue 2MRNA stabilityTranslational repressionEditing regulationA-to-I RNA editingLayer of epigenetic regulationSubstrate selectivityAdenosine-to-inosineLysine methyltransferase activityRNA editing levelsSensitivity of cancer cellsProstate cancerHistone modificationsTransportin-1Methyltransferase activityEditing levelsEpigenetic regulationUncharacterized roleEditing profilesADARADAR1RNAOncogene transcription
2025
Lineage plasticity and histological transformation: tumor histology as a spectrum
Li X, Gardner E, Molina-Pinelo S, Wilhelm C, Mu P, Quintanal-Villalonga Á. Lineage plasticity and histological transformation: tumor histology as a spectrum. Cell Research 2025, 35: 803-823. PMID: 41023204, PMCID: PMC12589604, DOI: 10.1038/s41422-025-01180-x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH Keywords and ConceptsConceptsHistological transformationLineage plasticityIn vivo modelsPatients treated with targeted therapyHigh risk of transformationResistance to anticancer therapiesMechanisms of tumor evolutionClinical settingRisk of transformationHuman tumor samplesAnalysis of human tumor samplesTumor histologyProstatic adenocarcinomaNeuroendocrine transformationTherapeutic overviewBiomarkers PredictiveTumor samplesLung adenocarcinomaAnticancer therapyMolecular findingsTumor evolutionMolecular driversTumorSquamous transdifferentiationTherapy
2024
Restoring our ubiquitination machinery to overcome resistance in cancer therapy
Li X, Mu P. Restoring our ubiquitination machinery to overcome resistance in cancer therapy. Oncoscience 2024, 11: 43-44. PMID: 38711948, PMCID: PMC11073315, DOI: 10.18632/oncoscience.600.Commentaries, Editorials and LettersCitationsAltmetricZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Xu Y, Yang Y, Wang Z, Sjostrom M, Jiang Y, Tang Y, Cheng S, Deng S, Wang C, Gonzalez J, Johnson N, Li X, Li X, Metang L, Mukherji A, Xu Q, Tirado C, Wainwright G, Yu X, Barnes S, Hofstad M, Chen Y, Zhu H, Hanker A, Raj G, Zhu G, He H, Wang Z, Arteaga C, Liang H, Feng F, Wang Y, Wang T, Mu P. ZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer. Cancer Discovery 2024, 14: 1496-1521. PMID: 38591846, PMCID: PMC11285331, DOI: 10.1158/2159-8290.cd-23-0539.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsLineage plasticityTherapy resistanceProstate cancerCancer cellsAndrogen receptorResistance to AR-targeted therapiesLuminal lineageAR-targeted therapiesOvercome therapy resistanceTransition of cancer cellsEpigenetic regulatory machineryBona fide coactivatorTherapy responseAR signalingEpigenetic rewiringDrug resistanceTherapeutic strategiesEpigenetic reprogrammingProstateTherapyCancerPhenotypic plasticityRegulatory machineryAndrogenTranscriptional programs
2023
UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance
Rodriguez Tirado C, Wang C, Li X, Deng S, Gonzalez J, Johnson N, Xu Y, Metang L, Sundar Rajan M, Yang Y, Yin Y, Hofstad M, Raj G, Zhang S, Lemoff A, He W, Fan J, Wang Y, Wang T, Mu P. UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance. Oncogene 2023, 43: 265-280. PMID: 38030789, PMCID: PMC10798893, DOI: 10.1038/s41388-023-02890-5.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAberrant androgen receptorProstate cancerAR ubiquitinationAR degradationAntiandrogen therapyResistance to antiandrogen therapyE2 ubiquitin-conjugating enzymeEnhanced AR signalingAndrogen receptor degradersAR protein levelsProstate cancer patientsUbiquitin-conjugating enzymeResistant tumorsPCa tumorsAR signalingAndrogen receptorAntiandrogen treatmentAntiandrogen resistanceAR proteinReceptor degradationProtein levelsOncogenic proteinsTumorTherapyProtein degradation processThe Critical Interplay of CAF Plasticity and Resistance in Prostate Cancer.
Li X, Mu P. The Critical Interplay of CAF Plasticity and Resistance in Prostate Cancer. Cancer Research 2023, 83: 2990-2992. PMID: 37504898, DOI: 10.1158/0008-5472.can-23-2260.Commentaries, Editorials and LettersCitationsAltmetricMeSH Keywords and ConceptsConceptsCastration-resistant prostate cancerAndrogen deprivation therapyProstate cancerAndrogen receptorCastration-resistant prostate cancer developmentDevelopment of castration-resistant prostate cancerGenetically engineered mouse modelsMyofibroblastic cancer-associated fibroblastsOvercome treatment resistanceCancer-associated fibroblastsIncreased tumor heterogeneityDeprivation therapyCRPC developmentProstate tumorsTumor microenvironmentLineage plasticityTreatment resistanceStromal compartmentStandard treatmentTumor heterogeneityCancer recurrenceDrug resistanceDisease progressionMouse modelSingle-cell RNA sequencing
2022
Author Correction: Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance
Deng S, Wang C, Wang Y, Xu Y, Li X, Johnson N, Mukherji A, Lo U, Xu L, Gonzalez J, Metang L, Ye J, Tirado C, Rodarte K, Zhou Y, Xie Z, Arana C, Annamalai V, Liu X, Vander Griend D, Strand D, Hsieh J, Li B, Raj G, Wang T, Mu P. Author Correction: Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance. Nature Cancer 2022, 3: 1271-1271. PMID: 36241729, PMCID: PMC9586863, DOI: 10.1038/s43018-022-00458-y.Commentaries, Editorials and LettersCitationsAltmetric
News
Copy Link
News
Get In Touch
Copy Link
Contacts
Email
Locations
300 George Street
Lab
New Haven, CT 06511
Social Media